RXC004 + pembrolizumab

**RXC004 + pembrolizumab** is an investigative combination therapy comprising RXC004 (zamaporvint), an oral small molecule inhibitor of Porcupine in the Wnt signaling pathway, and pembrolizumab, a monoclonal antibody PD-1 checkpoint inhibitor. RXC004 is designed to inhibit Wnt-ligand dependent tumor growth and modulate immune evasion, potentially sensitizing tumors to immune checkpoint blockade. This combination is being evaluated in Phase 2 clinical trials for genetically selected solid tumors, primarily advanced biliary tract cancer, microsatellite stable metastatic colorectal cancer (MSS mCRC), and RNF43-mutant pancreatic cancer. RXC004 aims to enhance the response to anti-PD-1 therapy in tumor types typically resistant to checkpoint inhibition by simultaneously blocking tumor growth signaling and overcoming immune escape mechanisms[1][2][3][4].

Other names

zamaporvint